Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Clinical Trial ID NCT01009801

Rank	Title	Journal	Year	PubWeight™‹?›
1	Major challenges limiting liver transplantation in the United States.	Am J Transplant	2011	1.50
2	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
3	Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.	J Hepatol	2013	1.22
4	Clinical trials in hepatocellular carcinoma: an update.	Liver Cancer	2013	0.99
5	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.	Liver Cancer	2012	0.98
6	Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial.	World J Hepatol	2016	0.84
7	Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.	World J Gastroenterol	2014	0.80
8	Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.	Ther Deliv	2011	0.77
9	The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials.	BBA Clin	2015	0.75